心力衰竭研究的神经心脏治疗 (NECTAR-HF) (NECTAR-HF)
心力衰竭研究的神经心脏治疗
The NECTAR-HF feasibility trial is designed to evaluate the application of right vagal nerve stimulation in heart failure patients with a New York Heart Association Class III, an ejection fraction equal to or less than 35 %, and a narrow QRS duration equal to or less than 130 ms.
研究概览
地位
详细说明
The objectives of this study are to assess the impact of right vagal nerve stimulation on left ventricular remodeling, functional capacity, quality of life, and other measures in heart failure patients over a 6-month period. In addition, the study will assess the safety of the NECTAR-HF study system over an 18-month period.
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
-
Göttingen、德国、37075
- Universitätsmedizin Göttingen
-
Hamburg、德国、20246
- Universitäres Herzzentrum GmbH, Universitätsklinikum Hamburg-Eppendorf
-
Leipzig、德国、04103
- Universitätsklinikum Leipzig
-
-
Brandenburg
-
Bernau bei Berlin、Brandenburg、德国、16321
- Immanuel Klinikum Bernau Herzzentrum Brandenburg
-
-
-
-
-
Milan、意大利、20162
- Azienda Ospedaliera Niguarda Cà Granda
-
Naples、意大利、80131
- A. O. Dei Colli - Monaldi
-
Pavia、意大利、27100
- Policlinico San Matteo
-
-
-
-
-
Prague、捷克语、15030
- Nemocnice Na Homolce
-
-
-
-
-
Brussels、比利时、1200
- UCL Bruxelles
-
-
-
-
-
Lille、法国、59037
- CHRU de Lille - Hôpital Cardiologique
-
-
Nancy
-
Vandœuvre-lès-Nancy、Nancy、法国、54500
- Centre d'Investigation Clinique Pierre Drouin, CHU de Nancy
-
-
-
-
-
London、英国、SE5 9RS
- King's College Hospital NHS Foundation Trust
-
-
England
-
Bristol、England、英国、BS2 8HW
- University Hospitals Bristol, NHS Foundation Trust
-
Liverpool、England、英国、L14 3PD
- Liverpool Heart and Chest Hospital, NHS Foundation Trust
-
London、England、英国、W1G 8PH
- The Heart Hospital, University College London Hospitals, NHS Foundation Trust
-
London、England、英国、W2 1NY
- Imperial College Healthcare NHS Trust, St. Mary's Hospital
-
-
-
-
-
Eindhoven、荷兰、5623EJ
- Catharina Ziekenhuis Eindhoven
-
Utrecht、荷兰、3584CX
- UMC Utrecht
-
-
-
-
-
Barcelona、西班牙、08036
- Hospital Clinic de Barcelona
-
Madrid、西班牙、28041
- Hospital Doce de Octubre
-
-
Navarre
-
Pamplona、Navarre、西班牙、31008
- Clínica Universitaria de Navarra, Avenida Pio XII s/n
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age 18 or above, and of legal age to give informed consent specific to national laws
- Willing and capable of providing informed consent
- Capable of participating in all testing associated with this clinical investigation
- Stable symptomatic heart failure NYHA class II-III
- Left ventricular (LV) ejection fraction equal or smaller than 35 %
- Left ventricular end diastolic diameter (LVEDD) of 5.5 cm or greater
- Prescribed to optimal pharmacologic therapy
Exclusion Criteria:
- QRS larger than 130 ms
- Patients who have been hospitalized for heart failure and who required the use of HF IV therapy within 30 days before enrollment
- Patients unable to tolerate anesthesia required for implant
- Patients with unstable angina, myocardial infarction, PTCA, coronary artery bypass graft, cerebral vascular accident, or transient ischemic attack within previous 90 days before enrollment
- Patients whose primary cause of heart failure is mitral or aortic valve disease, with a severe classification
- Patients with persistent or permanent atrial fibrillation within 90 days prior to enrollment
- Pacemaker indicated patients
- Patients whose heart failure is due to congenital heart disease
- Patients who have started treatment for sleep apnea or sleep disordered breathing with therapies to maintain airway patency (e.g., CPAP, Bi-PAP,APAP) with or without oxygen supplementation within the previous 6 months prior to enrollment
- Patients with hypertrophic obstructive cardiomyopathy or infiltrative cardiomyopathy (e.g. amyloidosis, sarcoidosis)
- Patients with documented chronic obstructive lung disease
- Patients on or indicated for renal dialysis
- Type 1 diabetic patients
- Type 2 diabetic patients that have been treated with insulin for more than 5 years prior to enrollment
- Patients with a life expectancy of less than 12 months per physician judgment
- Patients involved in any concurrent clinical investigation
- Women of childbearing potential who are or might be pregnant at the time of the study or breastfeeding
- Patients with a prior cardiac transplant or expecting a heart transplant operation within the next 12 months
- Patients with a prior vagotomy
- Patients with prior or existing vagal nerve stimulation treatment
- Patients implanted with any active implantable medical device other than a left sided single or dual chamber implantable cardioverter defibrillator (ICD) with bipolar sensing, or a left sided CRT device with each sensing channel programmed to either bipolar sensing or no sensing. All CRT patients must have had CRT for at least 1 year prior to enrollment. The total number of CRT patients will not exceed 30
- Patients with locally implanted semi-/permanent devices such as vascular catheters, etc. that would interfere with the NECTAR-HF study system
- Patients with previously implanted devices on the right side that became infected before removal
- Patients with previous neck surgery and resultant scar formation that interferes with the ability to implant the study system on the right side of the neck (Thyroid/parathyroid, carotid artery etc)
- Patients with known recurrent nerve paralysis
- Patients who have undergone radiotherapy for thyroid disease/cancer
- Patients who have existing or prior tracheotomy
- Patients with severe vertebral cervical disease and limited mobility in the neck; includes those that frequently wear a brace
- Patients with carotid murmur/vascular bruit/carotid artery lesion
- Patients with known/suspected vascular malformation in carotid/vertebral circulatory bed
- Patients who are likely to need an MRI of the neck area because of previous medical conditions
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:交叉作业
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Therapy
Implant of investigational device system for vagus nerve stimulation. Patients were randomized in a 2 : 1 ratio to receive therapy (VNS ON) or control (VNS OFF) for a 6-month period. The experimental arm was receiving vagus nerve stimulation during the first 6 months after implant. Titration during the randomization phase with delivery of highest tolerable by patient stimulation current. Blood Draw before implant and 6 months after implant. Titration after the randomization phase with adjustments of the chronically highest tolearble by patient current. |
Vagus nerve stimulation lead was wrapped around the right cervical vagus nerve and then connected to a stimulator permanently implanted in the right pectoral region. Amplitude of the chronically delivered vagus nerve stimulation in the experimental arm was adjusted to the highest tolerable by patient value. No chronically delivered vagus nerve stimulation in the control arm during the randomization phase. Amplitude of the chronically delivered vagus nerve stimulation was adjusted to the highest tolerable by patient value in all patients in both arms of the study. Blood draw before implant and 6 months after implant at the end of the randomization phase. |
|
假比较器:Control
Implant of investigational device system for vagus nerve stimulation. Control group was implanted with study system like the experimental arm, but was not receiving experimental vagus nerve stimulation therapy during the first 6 months after implant. 6-month after implant a cross-over took place and the control arm also started to receive experimental vagus nerve stimulation. Blood Draw before implant and 6 months after implant. Titration after the randomization phase with adjustments of the chronically highest tolearble by patient current. |
Vagus nerve stimulation lead was wrapped around the right cervical vagus nerve and then connected to a stimulator permanently implanted in the right pectoral region. Amplitude of the chronically delivered vagus nerve stimulation was adjusted to the highest tolerable by patient value in all patients in both arms of the study. Blood draw before implant and 6 months after implant at the end of the randomization phase. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Left Ventricular End-systolic Dimension (LVESD)
大体时间:LVESD at Baseline and at 6-months post Baseline
|
Change in the Left ventricular end-systolic dimension (LVESD) between Baseline and the value at the end of the randomization phase (6 months after Baseline) i.e. 6 months after vagus nerve stimulation in the THERAPY Arm. No Vagus nerve stimulation during that time window in the CONTROL Arm. The sign (- ) indicates a reduction in the LVESD. Minus means a reduction in LVESD. The change was calculated from two time points as the value at the later time point minus the value at the earlier time point (e.g., value at 6 months minus value at baseline). |
LVESD at Baseline and at 6-months post Baseline
|
|
Percentage of Surviving Participants
大体时间:18-months
|
As pre-specified in the study protocol, the All-cause Survival endpoint combined both groups into one analysis population. Subjects contributed data according to the follow-up period during they received VNS therapy (Implant through 18 months for Therapy subjects, 6 through 18 months for Control subjects). Control patients who exited the study in the first 6 months, or who did not have a 6 month visit, were excluded. |
18-months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
LVEF, Left Ventricular Ejection Fraction
大体时间:LVEF at Baseline and at 6-months after Baseline
|
LVEF, left ventricular ejection fraction. |
LVEF at Baseline and at 6-months after Baseline
|
|
Exercise Capacity, Peak VO2
大体时间:Measurements at Baseline and at 6-months after Baseline
|
Assessment of functional capacity (e.g., peak VO2) as measures related to patient heart failure status. |
Measurements at Baseline and at 6-months after Baseline
|
|
LVESV, Left Ventricular End Systolic Volume
大体时间:At Baseline and at 6-months after Baseline
|
Measurements of LVESV, left ventricular end systolic volume at Baseline and 6 months after Baseline in the Control Arm and in the Therapy Arm |
At Baseline and at 6-months after Baseline
|
合作者和调查者
调查人员
- 首席研究员:Faiez Zannad, M.D.、Centre d'Investigation Clinique (CIC), Batiment Louis Mathieu, CHU de Nancy
出版物和有用的链接
一般刊物
- De Ferrari GM, Tuinenburg AE, Ruble S, Brugada J, Klein H, Butter C, Wright DJ, Schubert B, Solomon S, Meyer S, Stein K, Ramuzat A, Zannad F. Rationale and study design of the NEuroCardiac TherApy foR Heart Failure Study: NECTAR-HF. Eur J Heart Fail. 2014 Jun;16(6):692-9. doi: 10.1002/ejhf.80. Epub 2014 May 20.
- Zannad F, De Ferrari GM, Tuinenburg AE, Wright D, Brugada J, Butter C, Klein H, Stolen C, Meyer S, Stein KM, Ramuzat A, Schubert B, Daum D, Neuzil P, Botman C, Castel MA, D'Onofrio A, Solomon SD, Wold N, Ruble SB. Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial. Eur Heart J. 2015 Feb 14;36(7):425-33. doi: 10.1093/eurheartj/ehu345. Epub 2014 Aug 31.
- De Ferrari GM, Stolen C, Tuinenburg AE, Wright DJ, Brugada J, Butter C, Klein H, Neuzil P, Botman C, Castel MA, D'Onofrio A, de Borst GJ, Solomon S, Stein KM, Schubert B, Stalsberg K, Wold N, Ruble S, Zannad F. Long-term vagal stimulation for heart failure: Eighteen month results from the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) trial. Int J Cardiol. 2017 Oct 1;244:229-234. doi: 10.1016/j.ijcard.2017.06.036. Epub 2017 Jun 10.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.